Visual acuity development after anti-vegf therapy in diabetic macular edema
DOI:
https://doi.org/10.33064/56lm20244618Keywords:
Diabetic Retinopathy, Macular Edema, Diabetes MellitusAbstract
Introduction: Diabetic macular edema is the most frequent cause of decreased visual acuity in diabetics. The therapy most used in this pathology is antiangiogenic therapy. Objective: Identify visual acuity modification in patients with macular edema due to diabetic retinopathy after antiangiogenic therapy. Material and methods: An observational, retrospective, non-randomized case study was carried out, convenience sampling, in a population of patients with macular edema due to diabetic retinopathy, a total of 304 medical charts were reviewed, by single blind and two different researchers. A total of 189 files where selected, including only those that had all the approvals according to the inclusion parameters during the period from January 2022 to November 2022. Results: 26 men and 19 women, 60 eyes considered (29 right and 31 left) presenting macular edema due to diabetic retinopathy under treatment with antiangiogenic therapy with Aflibercept, it was found that the lower macular thickness is, the better visual acuity (r=0.73), (p<0.001). Visual acuity changes went, on average, from 0.16 baseline to a result of 0.36, indicating that there is in average a 30% improvement in final visual acuity. Conclusion: Intravitreal injection with Aflibercept as a treatment for macular edema due to diabetic retinopathy shows an improvement in visual acuity by reducing macular thickness.
Fecha de recepción: 23/08/2023
Aceptación de originales: 13/09/2023
Downloads
Metrics
References
Genuth S, Alberti KG, Bennett P. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34:S62-9.
Muñoz de Escalona-Rojas JE, Quereda-Castañeda A, García-García O. Actualización de la retinopatía diabética para médicos de atención primaria: hacia una mejora de la medicina telemática. SEMERGEN-Medicina de Familia. 2016;172-6.
Aliseda D, Berástegui L. Retinopatía diabética. Anales del Sistema Sanitario de Navarra. 2008;31:23-34.
Gangwani RA, Lian JX, McGhee SM, Wong D, Li KK. Diabetic retinopathy screening: global and local perspective. Hong Kong Med J. 2016 oct;22(5):486-95. DOI: 10.12809/hkmj164844. Epub 2016 Aug 26.
Valea PRV, Jeffrey M Isnera, W Losordob D, F Symesc JFS, M Isner J. Factores de crecimiento para la angiogénesis terapéutica en las enfermedades cardiovasculares. Rev Esp de Card. 2001 oct; 1210 a 1224.
Muñoz de Escalona-Rojas JE, Quereda-Castañeda A, García-García O. Update of diabetic retinopathy for Primary Care physicians: Towards an improvement of telematic medicine. Medicina de Familia. SEMERGEN. 2016.42(3):172-176.
Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021 aug;12(8):1322-1325.
Xian Wang, Xiaoning He, Fang Qi, Jia Liu, Jing Wu. Different anti-vascular endothelial growth factor for patients with diabetic macular edema: A network meta-analysis. 2022 National library of Medicine 13:876386.
Andonegui J, Jiménez-Lasanta L. Edema macular diabético. Anales del Sistema Sanitario de Navarra. 2008;31:35-44.
Tenorio G, Ramírez-Sánchez V. Retinopatía diabética; conceptos actuales. Rev Méd del Hospital General de México. 2010;73(3):193-201.
Jiménez-Sierra, Cano-Hidalgo, Flores-Peredo. Primer consenso nacional de edema macular diabético. Rev Mex de Oft. 2021;95 supl. 1.
Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64. DOI: 10.2337/dc11-1909.
Bravo JD, Correa A, Bravo A, Bravo R, Villada OA. Retinopatía diabética y edema macular diabético en población de Antioquia. Estudio transversal. 2022;35(2):98-107.
Wells JA, Glassman AR, Ayala AR. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015 mar 26;372(13):1193-203. 2015 Feb 18.
Simó-Servat O, Hernández C, Simó R. Diabetic retinopathy in the context of patients with diabetes. Ophthalmic Research. 2019;62(4):211-7.
Sánchez Thorin JC, Chica LG, González AL, Bohórquez MC, Lizcano F, Ocampo HH et al. Panel de expertos sobre la atención inicial de la retinopatía diabética. ALAD. 2018;8(4):175-83.
Rodríguez-Guanare M. Edema macular diabético: definición epidemiología, factores de riesgo, patogénesis, diagnóstico y clasificación. Asociación Latinoamericana de Diabetes 2015;5:98-105.
Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M. Anti‐vascular endothelial growth factor for diabetic macular edema: a network meta‐analysis. Cochrane Database of Systematic Reviews 2023, Issue 6. Art. No. CD007419.
Guillermo E, Arellano Barriga V, Doimeadios Rodríguez E, Luis E, Larrea S, et al. Universidad de Ciencias Médicas Holguín CC BY-NC-SA. Tomografía por coherencia óptica macular y retinopatía diabética Macular optical coherence tomography and diabetic retinopathy
Recomendaciones E. GUÍA DE PRÁCTICA CLÍNICA gpc Diagnóstico y Tratamiento de RETINOPATÍA DIABÉTICA.
Fernandez-Vigo López JÁ, Fernández Rodríguez MI, Fernández Sabugal JB, Macarro A, Fandiño Fernández JM. Edema macular diabético: aspectos
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Luis Fernando Barba Gallardo, Regina Carneado Trejo, Blanca Briseida Castañeda Ruiz Esparza, José Luis Díaz-Rubio
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La revista Lux Médica está bajo una licencia de Creative Commons Reconocimiento-NoComercial-Compartir Igual 4.0 Internacional.
